Inhibikase Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-4.5M | $18.5K |
| FY2020 | — | $9.8M | $14.0M |
| FY2021 | $248.9K | $38.4M | $40.8M |
| FY2022 | — | $21.0M | $7.2M |
| FY2023 | $381.8K | $11.0M | $9.2M |
| FY2024 | — | $94.9M | $97.5M |
| FY2025 | — | $172.9M | $178.8M |